Given the clinical success of immune checkpoint blockade, much attention has been put on immune checkpoint molecules, especially programmed cell death protein 1 (PD-1), and its ligand PD-L1, which is expressed by cancer cells and immune cells (B-cells, T-cells, DC, and macrophages) [36,37]. Here, PDCD1 is linked to cancer.